Coming soon

Events

See what BetaGlue will attend
San Francisco - JP Morgan Health Conference

44th Annual J.P. Morgan

Healthcare Conference

January 12-15, 2026 | San Francisco, California

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
Spectrum Miami

Advancements in the fight against cancer

Spectrum Conference

January 15-17, 2026 | Miami (FL), USA

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
MioLive - Roma

World Congress of Interventional Oncology

MIOLive

January 26-27, 2026 | Rome

Register interest: info@betaglue.com


Gianluca
De Danieli
Head of Clinical Development

What we’re building

News

Discover the latest from our lab and clinic
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval
BetaGlue Therapeutics Belgium Ministry of Health PDAC Cnlinical trial

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) Milan, December 15th, 2025 (GlobeNewswire) – BetaGlue® Therapeutics (“BetaGlue” or the…

Read more
1200 800 Betaglue® Therapeutics
BetaGlue Therapeutics expands Clinical Trial in Italy to conduct its clinical study in unresectable locally advanced pancreatic cancer (uLA-PDAC)

BetaGlue Therapeutics expands Clinical Trial in Italy to conduct its clinical study in unresectable locally advanced pancreatic cancer (uLA-PDAC)

Milan, December 1st, 2025 (GlobeNewsire) BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining approval from the Italian Ministry of Health to conduct clinical study in Unresectable Locally Advanced…

Read more
1200 800 Betaglue® Therapeutics
MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

Milan, November 12, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today…

Read more
1200 800 Betaglue® Therapeutics